Read your latest personalised notifications
Sign in
No account yet? Start here
Don't miss out
Ok, got it
Access event page
Join Assistant Professor Mikhail Lukiyanov, Professor Thomas Kahan and Professor Jan Kovac.
Free for everyone
Overview
There is currently significant deficiency of preventive therapies and interventional therapies for stroke in Europe, with substantial geographical variations (for example in mechanical thrombectomy), despite the strength of evidence showing the need for these therapies. Comprehensive highlights from the conference should help to stimulate further improvement in this area.
Learning Objectives
Measure how much you learn from this webinar by taking the pre and post evaluation.
Register now
Assistant Professor Mikhail LukiyanovNational Research Center for Preventive MedicineClinical cardiology departmentMoscow, Russia
Professor Thomas Kahan, FESCKarolinska InstitutetDepartment of Clinical SciencesStockholm, Sweden
Professor Jan Kovac, FESCUniversity Hospitals of Leicester NHS TrustCardiology DivisionLeicester, UK
This webinar addresses general physicians and cardiologists who cater for patients with cardiovascular comorbidities (atrial fibrillation and coronary artery disease) requiring anticoagulation with antiplatelet therapies, and those wishing to update their scientific knowledge on the topic.
During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.
An application has been made to the EACCME® for CME accreditation of this event.
The webinar is available on PC and tablets. The use of a smartphone is not recommended.
To answer the MCQs during the live event, you must allow pop-up windows on your device.
A high-speed Internet connection is required (minimum 2 Mbps).
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 Biot
06903, Sophia Antipolis, FR
This programme is supported by Bayer in the form of an educational grant.
The scientific programme has not been influenced in any way by its sponsor.
Our mission: To reduce the burden of cardiovascular disease.
